Zeroing in on tumor-reactive TILs

Cancer Immunology Research

Volumn 4, Issue 9, 2016, Pages 719-

  Ohashi, Pamela S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; HETERODIMER; MELAN A; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL THERAPY; HUMAN; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; METASTATIC MELANOMA; MULTIPLE CANCER; NOTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ADOPTIVE IMMUNOTHERAPY; NEOPLASM;

CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 85016151513     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0179     Document Type: Note

References (4)

1. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.
2. FridmanWH,Pages F, Sautes-Fridman C, Galon J. Theimmune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12: 298-306.
3. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003;198:39-50.
4. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.